373 related articles for article (PubMed ID: 34440747)
1. The Roadmap of RANKL/RANK Pathway in Cancer.
Casimiro S; Vilhais G; Gomes I; Costa L
Cells; 2021 Aug; 10(8):. PubMed ID: 34440747
[TBL] [Abstract][Full Text] [Related]
2. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
3. The anti-tumor effect of RANKL inhibition in malignant solid tumors - A systematic review.
de Groot AF; Appelman-Dijkstra NM; van der Burg SH; Kroep JR
Cancer Treat Rev; 2018 Jan; 62():18-28. PubMed ID: 29154022
[TBL] [Abstract][Full Text] [Related]
4. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
5. The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL.
Simatou A; Sarantis P; Koustas E; Papavassiliou AG; Karamouzis MV
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066388
[TBL] [Abstract][Full Text] [Related]
6. Role of the RANK/RANKL pathway in breast cancer.
Kiesel L; Kohl A
Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
[TBL] [Abstract][Full Text] [Related]
7. The RANK-RANKL axis: an opportunity for drug repurposing in cancer?
Peters S; Clézardin P; Márquez-Rodas I; Niepel D; Gedye C
Clin Transl Oncol; 2019 Aug; 21(8):977-991. PubMed ID: 30656607
[TBL] [Abstract][Full Text] [Related]
8. Denosumab for the treatment of bone metastases in advanced breast cancer.
Casas A; Llombart A; Martín M
Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
[TBL] [Abstract][Full Text] [Related]
9. Targeting RANKL in breast cancer: bone metastasis and beyond.
Azim H; Azim HA
Expert Rev Anticancer Ther; 2013 Feb; 13(2):195-201. PubMed ID: 23406560
[TBL] [Abstract][Full Text] [Related]
10. Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas.
Zoi I; Karamouzis MV; Xingi E; Sarantis P; Thomaidou D; Lembessis P; Theocharis S; Papavassiliou AG
Breast Cancer Res; 2019 Dec; 21(1):132. PubMed ID: 31796128
[TBL] [Abstract][Full Text] [Related]
11. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.
Tan W; Zhang W; Strasner A; Grivennikov S; Cheng JQ; Hoffman RM; Karin M
Nature; 2011 Feb; 470(7335):548-53. PubMed ID: 21326202
[TBL] [Abstract][Full Text] [Related]
12. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
13. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
[TBL] [Abstract][Full Text] [Related]
15. RANKL/RANK: from bone loss to the prevention of breast cancer.
Sigl V; Jones LP; Penninger JM
Open Biol; 2016 Nov; 6(11):. PubMed ID: 27881737
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
17. RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.
van Dam PA; Verhoeven Y; Trinh XB; Wouters A; Lardon F; Prenen H; Smits E; Baldewijns M; Lammens M
Crit Rev Oncol Hematol; 2019 Jan; 133():85-91. PubMed ID: 30661662
[TBL] [Abstract][Full Text] [Related]
18. [Bone metastasis and RANKL].
Nakashima T
Clin Calcium; 2014 Aug; 24(8):1201-8. PubMed ID: 25065872
[TBL] [Abstract][Full Text] [Related]
19. Denosumab in breast cancer treatment.
Drooger JC; van der Padt A; Sleijfer S; Jager A
Eur J Pharmacol; 2013 Oct; 717(1-3):12-9. PubMed ID: 23545361
[TBL] [Abstract][Full Text] [Related]
20. RANKLed by the Complexity of Signaling in Breast Cancer Metastasis to the Brain.
Wang K; Hackney JR; Siegal GP; Wei S
Clin Breast Cancer; 2020 Oct; 20(5):e569-e575. PubMed ID: 32381383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
